JOOTRH launches advanced maternal health study to reduce delivery complications in Kenya

KENYA — Expectant mothers accessing healthcare services at the Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH) will soon experience significantly improved care as the Maternal and Newborn Health Study, known as PRISMA, enters its third phase.

The initiative represents a collaborative effort between JOOTRH, the Kenya Medical Research Institute (KEMRI), and the Liverpool School of Tropical Medicine.

Through data-driven clinical interventions, the program seeks to drastically reduce delivery complications while improving perinatal outcomes for mothers and their babies.

Partnership Framework Established

The transition to PRISMA III follows a high-level consultative meeting between project partners and JOOTRH Chief Executive Officer Dr. Joshua Clinton Okise.

During the discussions, stakeholders agreed to sign a memorandum of collaboration after conducting a comprehensive review of ethical considerations surrounding the study.

The meeting focused heavily on establishing robust ethical frameworks and maintaining research integrity.

Dr. Okise stressed the critical importance of data sovereignty, explaining that real-time access to research findings enables the hospital to actively utilize its own data for immediate decision-making and improved patient care.

Expanded Diagnostic Capabilities

PRISMA II laid a strong foundation by providing expectant women with comprehensive screenings for various conditions, including G6PD deficiency, malaria, kidney function issues, and blood lead levels.

The third phase now introduces even more sophisticated diagnostic tools and methodologies.

New features in PRISMA III include point-of-care ultrasound “blind sweeps” that allow for quick assessment of maternal and fetal wellbeing.

The program also incorporates confirmatory testing for urinary tract infections and sexually transmitted infections, ensuring that conditions are accurately diagnosed and promptly treated.

 Additionally, researchers have developed a robust empowerment questionnaire designed to evaluate the social wellbeing of participating women, recognizing that maternal health extends beyond physical conditions.

Revolutionary Neonatal Care Advancements

PRISMA III promises to transform neonatal care at JOOTRH through significant technological investments.

The study has facilitated the installation of a low-field Hyperfine MRI at the facility, representing a cutting-edge advancement in pediatric diagnostics.

This specialized equipment will monitor neurodevelopmental outcomes in children born to mothers with anemia, allowing clinicians to identify and address potential developmental challenges early.

The program extends beyond imaging technology to address common neonatal emergencies.

JOOTRH will enhance its capacity to manage respiratory distress syndrome and hypoxic injury through improved oxygen availability and advanced pulse oximetry monitoring systems.

These interventions address critical gaps in neonatal intensive care that have historically affected outcomes for vulnerable newborns.

Strengthening Human Resources

While equipment upgrades form a vital component of PRISMA III, the partnership places equal emphasis on developing human capital within the healthcare system.

Through the Emergency Triage Assessment and Treatment (ETAT) program, medical staff receive continuous training to identify and address care gaps effectively.

Regular audits conducted by the CHAMPS platform provide ongoing quality assurance and help identify areas requiring additional support or training.

This comprehensive approach ensures that mothers receive consistent, high-quality care from their first antenatal visit through delivery and into post-delivery follow-ups within the community.

The hospital administration has expressed interest in expanding the study’s scope to accommodate the region’s large population.

The PRISMA collaboration demonstrates how research and clinical practice can merge effectively to save lives while positioning the region competitively on the global healthcare stage.